Servier and Galapagos join hands in $2m-now, $260m-later oncology deal
This article was originally published in Scrip
Executive Summary
French company Servier and Belgium's Galapagos have entered into a multi-year strategic alliance to discover and develop new small molecule therapies for cancer, building on their existing relationship in the field of osteoarthritis.